Penn Park Capital Secures €750 Million from Leading European Pension Funds
Penn Park Capital Management Secures €750 Million in Discretionary Mandates from Leading European Pension Funds, with Further Commitments Already Scheduled for 2025.
LONDON, UK / ACCESSWIRE / November 1, 2024 / Penn Park Capital Management is pleased to announce that several prominent European pension funds have entrusted the firm with discretionary mandates totaling approximately €750 million, with an additional €1.3 billion commitment anticipated for 2025. Under these mandates, Penn Park will manage assets on behalf of several major pension funds, providing comprehensive investment management and strategic advisory services designed to maximize value and optimize returns in line with each fund's unique objectives.
Record-Breaking Year Driven by Strong Investment Performance
This milestone comes amid one of Penn Park Capital's most successful years, fueled by the strong performance of the firm's managed funds and private equity strategies, particularly in high-growth sectors such as Private Space Exploration, Telecommunications, and Artificial Intelligence (AI). By capitalizing on opportunities in these transformative areas, Penn Park has achieved returns that have outpaced all major index funds, underscoring the firm's ability to consistently generate value in emerging markets.
Expansion of Investment Reach Across Innovative Sectors
With this significant new capital under management, Penn Park is well-positioned to expand its investment reach across cutting-edge sectors, enabling institutional and retail investors alike to achieve targeted returns and strategic growth. This additional funding will support the firm's mission to provide clients with superior, research-driven investment strategies that align with both long-term trends and immediate growth opportunities.
Client Acquisition Drive for the Final Quarter of 2024
Building on this year's record performance, Penn Park is also launching a major client acquisition drive for the final quarter of 2024. To support growing demand from both institutional and retail clients, the firm is expanding its team, strengthening its capacity to deliver high-quality service and personalized investment solutions.
"We are honored to manage these discretionary assets on behalf of leading European pension funds," said Mr. Michael Horsham, Head of Business Development at Penn Park Capital Management. "Their confidence reflects our track record and expertise, particularly in the private equity sector, where we have consistently identified and leveraged transformative opportunities. This year's results validate the strength of our investment approach, and we look forward to supporting our clients with innovative, performance-oriented solutions."
Strategic Team Growth to Meet Increasing Demand
Looking ahead, the additional capital commitments anticipated for 2025 will allow Penn Park to deepen its focus on managed funds, private equity, and high-growth sectors with strong return potential. The firm remains dedicated to delivering value-driven strategies tailored to the specific goals of each discretionary mandate, ensuring these pension funds benefit from sophisticated, research-focused asset management.
In response to increased client demand, Penn Park Capital is strategically expanding its team, adding experienced portfolio managers, analysts, and client service professionals. This growth will enable the firm to maintain its high standard of personalized service while meeting the needs of an ever-growing client base.
About Penn Park Capital Management
Penn Park Capital Management is a leading European wealth management firm and fund manager, specializing in privately managed funds and private equity financing to provide clients with access to some of today's most promising sectors and asset classes. With a strong commitment to innovative, strategic investment solutions, Penn Park Capital serves both institutional and retail clients seeking superior returns and a forward-thinking approach to wealth management.
For media inquiries, please contact:
Esme Mcalley-Burnside
Media and PR Manager
Penn Park Capital Management
Email: esme.burnside@pennparkcapital.com
Web: www.pennparkcapital.com
Phone: Tel: +44(0)20 3773 7888
SOURCE: Penn Park Capital Management Limited
View the original press release on accesswire.com
Penn Park Capital Management Limited
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom